ISRCTN25479460已完成未知
Atomoxetine for Attention-deficit hyperActivity disorder Symptoms in children with pervasive developmental disorders: a pilot study
Accare (The Netherlands)0 个研究点目标入组 12 人开始时间: 2007年2月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
2006 results in https://pubmed.ncbi.nlm.nih.gov/17069549/ (added 26/03/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Males and females between the ages of at least six years of age and not more than 17 years of age at visit one
- •2. ASD (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition [DSM-IV TR] diagnosis of autistic disorder or Asperger?s disorder or Pervasive Developmental Disorder (PDD) not otherwise specified, established by clinical assessment and corroborated by Autism Diagnostic Interview scores
- •3. Patients must score greater than four on the Clinical Global Impressions (CGI)-severity scale with regard to ADHD symptoms and score at least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the Attention-Deficit/Hyperactivity Rating Scale four (ADHDRS-IV) Parent Version
- •4. Outpatients
- •5. Medication-free for at least two weeks for all psychotropic medications (four weeks for fluoxetine or neuroleptics)
- •6. Intelligence Quotient (IQ) of at least 70
- •7. Laboratory results, including serum chemistries, hematology, and urinalysis, show no significant abnormalities and there is no clinical information that, in the judgment of a physician, should preclude a patient?s participation at study entry
- •8. Patients and parents (legal representative) have been judged by the investigator to be reliable to keep appointments for clinic visits and all tests, including venapunctures, and examinations required by the protocol. Patients must also be able to swallow capsules (study drug)
排除标准
- •1. Patients who weigh less than 20 kg at study entry
- •2. Females with a positive beta-Human Chorionic Gonadotropin (HCG) pregnancy test
- •3. Patients with a history of severe allergies to more than one class of medications or multiple adverse drug reactions
- •4. DSM-IV TR diagnosis of a PDD other than Autistic Disorder, PDD- Not Otherwise Specified, Asperger?s Disorder (e.g., Rett?s Disorder, Childhood Disintegrative Disorder), schizophrenia, another psychotic disorder, substance abuse
- •5. A significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, or seizure disorder identified by history, physical examination, or laboratory tests
研究者
相似试验
已完成
不适用
Atomoxetine in children with pervasive developmental disorders.Atomoxetine treatment.NL-OMON21784Accare, division University Center for Child and Adolescent Psychiatry, PO Box 660, 9700 AR Groningen, The Netherlands12
撤回
4 期
Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUDSubstance Use DisorderAttention Deficit Hyperactivity DisorderNCT01207622Massachusetts General Hospital
已完成
不适用
The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults ADHDAttention Deficit Hyperactivity DisorderNCT00917371National Taiwan University Hospital60
已完成
不适用
Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment FacilityAttention Deficit Hyperactivity DisorderNCT00953862NYU Langone Health18
已完成
4 期
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional OutcomesAttention Deficit Hyperactivity DisorderNCT00510276Eli Lilly and Company445
